Stocks
Funds
Screener
Sectors
Watchlists
IMMX

IMMX - Immix Biopharma, Inc. Common Stock Stock Price, Fair Value and News

$10.00-0.11 (-1.09%)
Market Closed

Price Targets

IMMX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

IMMX Price Action

Last 7 days

7.6%

Last 30 days

46.2%

Last 90 days

41.4%

Trailing 12 Months

532.9%

IMMX RSI Chart

IMMX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

IMMX Valuation

Market Cap

335.8M

Price/Earnings (Trailing)

-14.27

EV/EBITDA

-13.72

Price/Free Cashflow

-21.73

MarketCap/EBT

-14.27

IMMX Price/Earnings (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

IMMX Fundamentals

IMMX Earnings

Earnings (TTM)

-23.5M

Earnings Growth (Yr)

-6.3%

Earnings Growth (Qtr)

-14.76%

IMMX Profitability

Return on Equity

-284.75%

Return on Assets

-117.2%

Free Cashflow Yield

-4.6%

IMMX Investor Care

Shares Dilution (1Y)

22.07%

Diluted EPS (TTM)

-0.76

IMMX
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
 CEO
 WEBSITEimmixbio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES9

Immix Biopharma, Inc. Common Stock Frequently Asked Questions


IMMX is the stock ticker symbol of Immix Biopharma, Inc. Common Stock. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Immix Biopharma, Inc. Common Stock is 335.78 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.